



RESEARCH ARTICLE

Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer

Xiaowen Liu^{1,2,3} | Danwen Qian^{2,3} | Hongliang Liu^{3,4} | James L. Abbruzzese^{3,4} | Sheng Luo⁵ | Kyle M. Walsh^{3,6} | Qingyi Wei^{3,4,7} 

¹Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

²Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

³Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina

⁴Department of Medicine, Duke University School of Medicine, Durham, North Carolina

⁵Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina

⁶Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina

⁷Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina

Correspondence

Qingyi Wei, Department of Population Health Sciences, Duke University Medical Center and Duke Cancer Institute, Duke School of Medicine, 905 S LaSalle Street, Durham, NC 27710.

Email: qingyi.wei@duke.edu

Funding information

P30 Cancer Center Support Grant, Grant/Award Number: CA014236; National Cancer Institute, Grant/Award Numbers: HHSN261200800001E, K07 CA140790, R01CA154823; American Society of Clinical Oncology Conquer Cancer Foundation; Howard Hughes Medical Institute; Lustgarten Foundation; Robert T. and Judith B. Hale Fund for Pancreatic Cancer Research; Promises for Purple; National Institutes of Health, Grant/Award Number: HHSN2682011000111

Abstract

Because the peroxisome proliferator-activated receptor (PPAR) signaling pathway is involved in development and progression of pancreatic cancer, we investigated associations between genetic variants of the PPAR pathway genes and pancreatic cancer risk by using three published genome-wide association study datasets including 8477 cases and 6946 controls of European ancestry. Expression quantitative trait loci (eQTL) analysis was also performed for correlations between genotypes of the identified genetic variants and messenger RNA (mRNA) expression levels of their genes by using available databases of the 1000 Genomes, TCGA, and GTEx projects. In the single-locus logistic regression analysis, we identified 1141 out of 17 532 significant single-nucleotide polymorphisms (SNPs) in 112 PPAR pathway genes. Further multivariate logistic regression analysis identified three independent, potentially functional loci (rs12947620 in *MED1*, rs11079651 in *PRKCA*, and rs34367566 in *PRKCB*) for pancreatic cancer risk (odds ratio [OR] = 1.11, 95% confidence interval [CI], [1.06-1.17], $P = 5.46 \times 10^{-5}$; OR = 1.10, 95% CI, [1.04-1.15], $P = 1.99 \times 10^{-4}$; and OR = 1.09, 95% CI, [1.04-1.14], $P = 3.16 \times 10^{-4}$, respectively) among 65 SNPs that passed multiple comparison correction by false discovery rate (< 0.2). When risk genotypes of these three SNPs were combined, carriers with 2 to 3 unfavorable genotypes (NUGs) had a higher risk of pancreatic cancer than those with 0 to 1 NUGs. The eQTL analysis showed that rs34367566 A>AG was associated with decreased expression levels of *PRKCB* mRNA in 373 lymphoblastoid cell lines. Our findings indicate that genetic variants of the PPAR pathway genes, particularly *MED1*, *PRKCA*, and *PRKCB*, may contribute to susceptibility to pancreatic cancer.

KEYWORDS

genome-wide association study, pancreatic cancer susceptibility, pathway analysis, PPAR, single-nucleotide polymorphism

Abbreviations: CIs, confidence intervals; eQTL, expression quantitative trait loci; FDR, false discovery rate; GTEx, genotype-tissue expression project; GWAS, genome-wide association study; LD, linkage disequilibrium; MMR, mismatch repair; NUGs, number of unfavorable genotypes; ORs, odd ratios; PC, principal components; PKC, protein kinase C; PPAR γ , peroxisome proliferator-activated receptor gamma; PPARs, peroxisome proliferator-activated receptors; SNPs, single-nucleotide polymorphisms; TCGA, The Cancer Genome Atlas.

[†]Xiaowen Liu and Danwen Qian contributed equally to this work.

1 | INTRODUCTION

Pancreatic cancer is one of the deadliest human cancers, and it is the seventh most common cause of cancer deaths worldwide¹ and the fourth leading cause of cancer-related deaths in the USA.² Notably, the incidence has sharply increased up to 15.5/1 000 000 in the past decades.³ Many epidemiological studies have consistently reported that some host factors, such as smoking, overweight, a history of diabetes, or chronic pancreatitis are risk factors for pancreatic cancer.⁴⁻⁷ Recently, accumulating evidence suggests that genetic factors also contribute to the development of pancreatic cancer,^{8,9} because individuals with a family history of pancreatic cancer are more likely to develop this disease than those without a family history.⁶ Among the genetic factors, single-nucleotide polymorphisms (SNPs) are the most common type of genetic variation in human genomes and have been identified to be associated with pancreatic cancer risk.⁹⁻¹¹ Therefore, pancreatic cancer as a complex disease is also likely to have a complex interplay between environmental and genetic factors.

Genome-wide association study (GWAS) examines hundreds of thousands of SNPs across the genome at the same time in a hypothesis-free manner, making it a promising approach to studying susceptibility to complex diseases, including cancer. GWASs have been used to identify pancreatic cancer susceptibility loci in different ethnic populations.¹²⁻¹⁸ To date, a total of 13 loci (9q34.2, 13q22.1, 17q24.3, 7q23.2, 5p15.33, 1q32.1, 16q23.1, 13q12.2, 2p14, 22q12.1, 7p14.1, and 3q28, 8q24.1) have been reported to be associated with pancreatic cancer risk in populations of European ancestry.¹²⁻¹⁶ In addition, some pancreatic cancer susceptibility loci have also been reported in Chinese and Japanese populations.^{17,18} However, based on the stringent genome-wide significance level of $P < 5 \times 10^{-8}$, many potential cancer risk-associated variants may not be detected due to their weak effects at the GWAS level.¹⁹ Recently, the pathway-based analysis of GWAS data sets has been used as a useful hypothesis-driven strategy to search for additional SNPs in multiple genes of a particular biological pathway for susceptibility to complex disease, including cancer.²⁰⁻²² Several biological pathways have been suggested as candidate pathways for pancreatic carcinogenesis, such as the platelet-derived growth factor pathway,²³ the neuroactive ligand receptor interaction pathway and the olfactory transduction pathways²⁴ as well as the pancreatic development pathway.²⁵

Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. PPARs play crucial roles in the regulation of cellular differentiation, development, metabolism, and tumorigenesis. Genetic variants in genes encoding these receptors are thought to contribute to carcinogenesis.²⁶⁻²⁸ For example, the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma (PPARG) was found to be a risk factor for gastric cancer,²⁶ while PPAR alpha and gamma were found to be associated with breast cancer risk.²⁷ Another study found that the Pro12Ala polymorphism in PPARG could confer susceptibility to pancreatic cancer.²⁸

Although the above-mentioned studies have investigated associations between SNPs in PPAR pathway genes and cancer risk, only a limited number of variants in few candidate genes were included in those studies with limited sample sizes. Thus, there is a need to perform a holistic analysis of SNPs in all genes involved in the PPAR pathway for their contribution to pancreatic cancer susceptibility. In the present study, therefore, we examined associations between 17 532 genetic variants of 112 PPAR pathway genes and pancreatic cancer risk in 8477 pancreatic cancer cases and 6946 cancer-free controls of European ancestry.

2 | MATERIALS AND METHODS

2.1 | Study populations

The subjects included in the present study has been described in a previous publication.²³ Briefly, there are two published GWASs with available genotyping data to be used for the present study, which include the PanScan study and the Pancreatic Cancer Case Control Association Study. The PanScan study consisted of 5213 cases and 3905 controls,¹²⁻¹⁵ while the Pancreatic Cancer Case Control Association Study was obtained from the Pancreatic Cancer Case-Control consortium (PanC4), consisting of 4168 cases and 3814 controls from the USA, Europe, and Australia.¹⁶ To focus on the subjects of European ancestry, we included 15 423 individuals (8477 cases and 6946 controls) (Table S1) in the final analysis. A written informed consent was obtained from each participant for the PanScan study, the present study protocol was approved by Duke University Medical Center Institutional Review Board, and the GWAS data access was granted by National Center for Biotechnology Information for dbGaP accession# phs000206.v5.p3 and dbGaP accession# phs000648.v1.p1.

2.2 | Gene and SNP selection

To define the pathway to be investigated, the PPAR pathway genes were collected from Molecular Signatures Database (<http://www.broadinstitute.org/gsea/msigdb/index.jsp>) by the keyword "peroxisome proliferator-activated receptor" or "PPAR." In total, 112 genes were selected as candidate genes after removing duplicate genes and genes located in X chromosome (Table S2).

SNP imputation was performed with a 250-kb buffer region on each side of the 112 genes with IMPUTE2 based on the 1000 Genomes Project (panel 3) (Figure S1). After quality control for SNPs, there were 20 507, 23 324, and 20 230 SNPs within the genes with their ± 2 kb flanking regions for PanScan I, PanScan II/III, and PanC4, respectively. The final 17 532 SNPs from each of the three data sets were included in a meta-analysis according to the following criteria: a minor allele frequency greater than or equal to 0.01, a genotyping rate greater than or equal to 95%, and Hardy-Weinberg equilibrium P value $\geq 1 \times 10^{-5}$. All remaining SNPs also passed the quality control of imputation with an info score greater than or equal to 0.40 in IMPUTE2.

2.3 | Functional annotation and eQTL analysis

Functional prediction of the identified SNPs was performed by using three online tools: SNPinfo (<https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>), RegulomeDB (<http://www.regulomedb.org/>), and HaploReg (<http://archive.broadinstitute.org/mammals/haploreg/haploreg.php>). SNPinfo is a website with a suite of tools for single-nucleotide polymorphism detection; RegulomeDB is a website that allows one to identify DNA features and regulatory elements in noncoding regions of the human genome; and HaploReg is a tool for exploring annotations of the noncoding genome at variants on haplotype blocks, such as candidate regulatory SNPs at disease-associated loci.

We performed the expression quantitative trait loci (eQTL) analysis to investigate the correlations between genotypes of the identified SNPs and messenger RNA (mRNA) expression levels of the corresponding genes. Data from other three sources were also used, including the 1000 Genomes Project, the Cancer Genome Atlas (TCGA) (<http://tcga-data.nci.gov/tcga/>), and the Genotype-Tissue Expression project (GTEx). In the 1000 Genomes Project, the mRNA expression data were from the lymphoblastoid cell lines of 373 Europeans. In the TCGA, there were genotype and phenotype data for 127 Europeans, while GTEx was an online database of 663 samples with various genotype and gene expression data from different tissues. In addition, OncoPrint database was used to compare mRNA expression levels between normal and tumor tissues (<https://www.oncoPrint.org/>).

2.4 | Statistical analysis

There were 20 principal components (PCs) in the pancreatic cancer GWAS data sets, and these 20 PCs were first analyzed for their associations with pancreatic cancer risk by univariate logistic regression analysis (Table S3). As a result, the top five significant PCs with P value $< .001$ were included as covariates for the adjustment in further multivariate analyses. For each SNP, odd ratios (ORs) and 95% confidence intervals (CIs) were estimated in a single-locus analysis by unconditional logistic regression with adjustment for age, sex, and significant PCs by using PLINK 1.9. Cochran's Q statistics and I^2 were performed to estimate heterogeneity. If there was no heterogeneity ($I^2 < 50\%$ and Q -test $P > .1$), a meta-analysis in fixed-effects models was used to calculate associations between SNPs and pancreatic cancer risk in the combined data set of all three studies. The false discovery rate (FDR) with a cutoff 0.2 for multiple comparison correction was used to reduce the probability of false-positive findings. The independent SNPs were further determined by the stepwise multivariate logistic regression analysis with adjustment for other available covariates and previously published risk-associated SNPs from the same study populations. The risk associated with genotypes of the identified significant and independent SNPs was further assessed in a genetic score (the combined genotypes) and in stratified analyses by the available covariates. In the eQTL analysis, associations between

genotypes of the SNPs and mRNA expression levels were calculated by using a general linear regression model. Manhattan plots and linkage disequilibrium (LD) plots were made by Haploview v4.2. Regional association plots were generated by LocusZoom (<http://locuszoom.sph.umich.edu/locuszoom/>). Unless specified otherwise, all statistical analyses were performed using R (version 3.2.2), SAS (version 9.4; SAS Institute, Cary, NC), and PLINK (version 1.07).

3 | RESULTS

3.1 | Subject characteristics

The final analysis included 8477 cases and 6946 controls whose demographic characteristics have been described previously (Table S1). In brief, sex was similarly distributed between the case and control groups in all three studies, but the cases were younger than the controls in all three studies.

3.2 | Associations between SNPs and pancreatic cancer risk

The study workflow is outlined in Figure 1. There were 20 507, 23 324, and 20 230 SNPs in PanScan I, PanScan II/III, and PanC4, respectively. The single-locus analysis showed that there were 1338, 1171, and 1036 SNPs with a nominal $P < .05$ in PanScan I, PanScan II/III, and PanC4, respectively (Figure S2). Then, a meta-analysis using the summary genotyping data from these three GWASs was performed. An overview of overall associations is shown in a Manhattan plot (Figure 2A). A total of 1141 SNPs of 112 PPAR pathway genes were identified with a nominal $P < .05$ in the meta-analysis. Of these, 65 SNPs in *MED1*, *PRKCA*, and *PRKCB* remained statistically significant after multiple test correction by $FDR < 0.2$. Of these 65 SNPs, there were 46 SNPs in *MED1*, one SNP in *PRKCA*, and 18 SNPs in *PRKCB*. More detailed information for 65 SNPs (including position, effect allele, relative minor allelic frequency, effect sizes, FDR, and adjusted P values) are summarized in Table 1 and Table S4.

3.3 | LD analysis and functional prediction

Because there was only one SNP in *PRKCA*, we performed the LD analysis for *MED1* and *PRKCB*. The results showed that two blocks (of seven and 35 SNPs) shared a high LD in *MED1*, respectively ($r^2 \geq .80$; Figure 2B,C), and another 17 SNPs shared a high LD in *PRKCB* ($r^2 \geq .80$; Figure 2D,E). Functional prediction was performed for these 65 SNPs by using SNPinfo, RegulomeDB, and HaploReg. According to the LD map and online functional prediction (Table S5), five SNPs (rs12947620, rs8076041, and rs12945015 in *MED1*, rs34367566 in *PRKCB*, and rs11079651 in *PRKCA*) were selected as the tagSNPs for further analysis.




FIGURE 1 The workflow of the analysis. eQTL, expression quantitative trait loci; FDR, false discovery rate; HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; PanC, pancreatic cancer; PPAR, peroxisome proliferator-activated receptor; SNP, single-nucleotide polymorphism

3.4 | Independent associations between SNPs and pancreatic cancer risk

Then, we included the five potentially functional SNPs (ie, rs12947620, rs8076041, rs12945015, rs34367566, and rs11079651) in a multivariate stepwise logistic regression model. After adjustment for sex, age, and the top five PCs ($P < .001$), three SNPs (ie, rs12947620, rs11079651, and rs34367566) were found to be independently associated with pancreatic cancer risk (Table 2). Furthermore, we put these three SNPs and all 13 previously published risk-associated SNPs from the same study populations of pancreatic cancer studies into a multivariate model and found that all of these three SNPs remained significantly associated with pancreatic cancer risk (Table S6).

Specifically, the SNP rs12947620 C>T was significantly associated with risk in all genetic models. In an additive model, there was a linear trend between the number of rs12947620 T allele and pancreatic cancer risk ($P_{\text{trend}} < .001$), while the SNP rs11079651 C>T was also significantly associated with risk in all genetic models with a linear trend ($P_{\text{trend}} = .0001$). Similarly, the SNP rs34367566 A>AG was significantly associated with pancreatic cancer risk only in additive and dominant models. In the additive model, carriers with the rs34367566 AG allele had a high risk of pancreatic cancer, and the risk increased as the number of minor alleles increased ($P_{\text{trend}} = .0004$) (Table 3). Compared with the reference genotype in a dominant genetic model, carriers with *MED1* rs12947620 CT+TT, *PRKCA*

rs11079651 CT+TT, and *PRKCB* rs34367566 A/AG+AG/AG genotypes had a higher risk of pancreatic cancer (OR=1.12, 95% CI, 1.05-1.19, $P = .0008$; OR = 1.12, 95% CI, 1.05-1.19, $P = .0008$; and OR = 1.14, 95% CI, 1.06-1.22, $P = .0002$; respectively).

3.5 | Combined and stratified analyses

In a dominant model, we combined risk genotypes (ie, rs12947620 CT+TT, rs11079651 CT+TT, and rs34367566 A/AG+AG/AG) into a single variable as the number of unfavorable genotypes (NUGs) that were further divided into: 0, 1, 2, and 3. The trend test showed that there was a significant trend in association of an increased NUGs with an increased pancreatic cancer risk ($P < .0001$, Table 3). We further dichotomized all the subjects by NUG into two groups: low-score group (0-1) and high-score group (2-3). Compared with the low-score group, individuals of the high-score group had a significantly higher risk of developing pancreatic cancer (OR = 1.20, 95% CI = 1.12-1.28, $P < .0001$). Using this dichotomized variable, we further performed stratified analysis by age and sex to investigate their interactions with the combined risk genotypes on pancreatic cancer risk. We found that those with a high NUG score had a higher risk of pancreatic cancer than those of the low-score group in both males and females, but the results were similar among different age groups (<60, 60-70, and >70); thus, there was no statistical evidence for an interaction. (Table S7).




FIGURE 2 Screening for pancreatic cancer (PanC) risk-associated single-nucleotide polymorphisms (SNPs). (A) Manhattan plot of the association results of 17 532 SNPs in 112 peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and PanC risk in the meta-analysis of three genome-wide association study (GWAS) data sets. Blue horizontal line indicates $P = .05$ and red horizontal line indicates false discovery rate (FDR) = 0.2. (B) Regional association plot and (C) Linkage disequilibrium plot of significant SNPs of the *MED1* gene. (D) Regional association plot and (E) Linkage disequilibrium plot of significant SNPs of the *PRKCB* gene [Color figure can be viewed at wileyonlinelibrary.com]

TABLE 1 Associations between three independently pancreatic cancer risk-associated SNPs in the PPAR signaling pathway

SNP	Gene	Chr.	Position	Allele ^a	EAF1 ^b	EAF2 ^b	EAF3 ^b	OR (95% CI) ^c	P ^d	FDR
rs12947620	<i>MED1</i>	17	37605364	T/C	0.2531	0.2512	0.2521	1.11 (1.06-1.17)	5.46×10 ⁻⁵	0.026
rs11079651	<i>PRKCA</i>	17	64346169	T/C	0.3177	0.3045	0.2991	1.10 (1.04-1.15)	1.99×10 ⁻⁴	0.090
rs34367566	<i>PRKCB</i>	16	23935503	AG/A	0.4135	0.4217	0.4249	1.09 (1.04-1.14)	3.16×10 ⁻⁴	0.129

Abbreviations: Chr, chromosome; EAF, effect allele frequency; FDR, false discovery rate; PanC4, pancreatic Cancer Case-Control consortium; OR, odds ratio; SNP, single-nucleotide polymorphism.

^aEffect allele/reference allele.

^bEAF1 was EAF in PanScan I controls; EAF2 was EAF in PanScan II/III controls; EAF3 was EAF in PanC4 controls.

^cFixed-effects models were used when no heterogeneity was found between studies ($Q_{\text{test}} P > .10$ and $I^2 < 50.0\%$); otherwise, random effects models were used.

^dMeta-analysis of the three studies.

3.6 | eQTL analysis

We also performed eQTL to investigate the correlations between variant genotypes and their gene expression levels. By using the available data on genotypes and gene expression in the 1000 Genomes Project, we found that the rs34367566 genotypes were significantly associated with a decreased mRNA expression level of *PRKCB* in both additive and recessive models ($P = .037$ and $P = .046$, respectively; Figure 3), but not for other two SNPs (*MED1* rs12947620 and *PRKCA* rs11079651); however, none of positive correlations were observed in the TCGA database, and no data for three SNPs available in the online GTEx database. Finally, we found that expression levels of all three genes, *MED1*, *PRKCA*, and *PRKCB*, were higher in tumor tissues than in normal tissues in the OncoPrint database (Figure S3).

4 | DISCUSSION

Prior studies have reported associations between genetic variants in PPAR pathway genes and risk of cancers of the stomach, breasts, and pancreas²⁶⁻²⁸ for a limited number of variants in a small number of candidate genes. These candidate gene studies typically investigated the PPAR alpha and gamma genes in populations with limited sample sizes. In the present study, we investigated the associations between

17 532 genetic variants of 112 PPAR pathway genes and pancreatic cancer risk in 8477 cases with pancreatic cancer and 6946 controls. We found that *MED1* rs12947620, *PRKCA* rs11079651, and *PRKCB* rs34367566 were significantly associated with an increased risk of pancreatic cancer in populations of European ancestry. Furthermore, functional prediction analyses showed that the rs34367566 variant AG allele was associated with a decreased mRNA expression level of *PRKCB*. Interestingly, we also found that the expression levels of all three genes, *MED1*, *PRKCA*, and *PRKCB*, were higher in tumor tissues than in normal tissues, suggesting an oncogenic role of the PPAR pathway genes in pancreatic cancer. To the best of our knowledge, the present study is the first to comprehensively evaluate the roles of common genetic variants in associations between all the PPAR pathway genes and pancreatic cancer risk.

The *MED1* gene, also known as *MED4* harboring the most significantly risk-associated SNP rs12947620, encodes a protein called the mediator of RNA polymerase II transcription subunit 1. This protein has been reported to be involved in several cellular processes, including apoptotic response to DNA damage,²⁹ transcriptional repression,³⁰ and chromosomal stability.³¹ In addition, *MED1* can bind to the mismatch repair (MMR) protein MLH1 and modulate expression levels of the core MMR proteins.³² Studies have shown that *MED1* mutations frequently occurred in cancers with microsatellite instability, including pancreatic cancer,³³⁻³⁵ while other studies indicated that *MED1* suppressed mutations at CpG sites in

TABLE 2 SNPs as independent predictors for pancreatic cancer risk evaluated by stepwise logistic regression analysis^a

Parameter	Subgroup	β	SE	χ^2	OR (95% CI)	P ^b
Sex	Male vs female	-.004	0.03	0.02	1.00 (0.93-1.06)	.8946
Age	60-70 vs <60	.132	0.04	10.22	1.14 (1.05-1.24)	.0014
Age	>70 vs <60	.191	0.04	21.75	1.21 (1.12-1.31)	<.0001
rs34367566	AG/A	.085	0.02	13.04	1.09 (1.04-1.14)	.0003
rs12947620	T/C	.110	0.03	17.75	1.12 (1.06-1.18)	<.0001
rs11079651	T/C	.096	0.02	15.09	1.10 (1.05-1.16)	.0001

Abbreviations: CI, confidence interval; OR, odds ratio; SE, standard error; SNPs, single-nucleotide polymorphisms.

^a15 Subjects with missing date were excluded.

^bStepwise analysis included age, sex, top five PC (principal components) and five SNPs (rs12947620, rs12945015, rs8076041, rs11079651, and rs34367566).

TABLE 3 Associations between genotypes of three SNPs and pancreatic cancer risk

Genotype	Group		OR (95% CI) ^a	P ^a
	Case (%)	Control (%)		
rs34367566 A>AG				
A/A	2578 (30.41)	2347 (33.79)	1.00	–
A/AG	4231 (49.91)	3347 (48.19)	1.13 (1.05-1.22)	.0009
AG/AG	1668 (19.68)	1252 (18.02)	1.16 (1.06-1.28)	.0014
Trend test				.0004
A/AG+AG/AG	5899 (69.59)	4599 (66.21)	1.14 (1.06-1.22)	.0002
AG/AG	1668 (19.68)	1252 (18.02)	1.08 (1.00-1.17)	.0668
rs12947620 C>T				
C/C	4477 (52.81)	3877 (55.82)	1.00	–
C/T	3335 (39.34)	2635 (37.93)	1.09 (1.02-1.16)	.0170
T/T	665 (7.85)	434 (6.25)	1.30 (1.14-1.48)	<.0001
Trend test				<.0001
C/T+T/T	4000 (47.19)	3069 (44.18)	1.12 (1.05-1.19)	.0008
T/T	665 (7.85)	434 (6.25)	1.26 (1.11-1.43)	.0004
rs11079651 C>T ^b				
C/C	3890 (45.92)	3366 (48.49)	1.00	–
C/T	3663 (43.23)	2915 (41.99)	1.09 (1.02-1.17)	.0096
T/T	919 (10.85)	661 (9.52)	1.21 (1.09-1.36)	.0006
Trend test				.0001
C/T+T/T	4582 (54.08)	3576 (51.51)	1.12 (1.05-1.19)	.0008
T/T	919 (10.85)	661 (9.52)	1.16 (1.05-1.29)	.0051
Number of unfavorable genotype ^c				
0	598 (7.06)	596 (8.58)	1.00	–
1	2767 (32.66)	2485 (35.80)	1.09 (0.96-1.24)	.1733
2	3614 (42.66)	2830 (40.77)	1.24 (1.10-1.41)	.0006
3	1493 (17.62)	1031 (14.85)	1.40 (1.22-1.61)	<.0001
Trend test				<.0001
0-1	3365 (39.72)	3081 (44.38)	1.00	–
2-3	5107 (60.28)	3861 (55.62)	1.20 (1.12-1.28)	<.0001

Abbreviations: CI, confidence interval; OR, odds ratio; SNPs, single-nucleotide polymorphisms.

^aAdjusted for age, sex, and top five principle components.

^bNine subjects with missing data were excluded.

^cRisk genotypes were rs12947620 C/T+T/T, rs11079651 C/T+T/T, and rs34367566 A/AG+AG/AG.

mammalian genomes and that its loss could promote tumor formation.^{36,37} However, the exact molecular mechanism how *MED1* rs12947620 may increase pancreatic cancer risk is not fully understood yet, which requires additional mechanistic and functional studies.

The *PKC* gene, tagged by two other risk-associated SNPs rs11079651 and rs34367566 identified in the present study, encodes a protein called protein kinase C (PKC), a family of homologous serine/threonine protein kinases. It is known that PKC participates in diverse cellular process by transducing signals, including proliferation, differentiation, apoptosis, and angiogenesis.³⁸ The PKC family is subdivided into three groups, the classical PKC (cPKC), novel PKC, and atypical PKC, of which the classical PKCs include PKC α , PKC β , PKC β II, and PKC γ .^{39,40} The two SNPs identified in the present study belong to cPKC, a protein that regulates many aspects of

tumorigenesis, including initiation, progression, and metastasis.⁴¹ Although different isoforms have different roles, they all act to influence similar signaling pathway downstream genes. For example, cPKCs are mainly activated by growth factors such as epidermal growth factor and oxidative stress, leading to the activation of transcription factors, such as nuclear factor- κ B, signal transducer, and activator of transcription. Both proteins have been demonstrated to play a role in metastasis and survival in patients with pancreatic cancer.⁴²⁻⁴⁴ In the present study, we found that rs34367566 AG variant genotypes were significantly associated with a decreased mRNA expression level of *PRKCB* in both additive and recessive models. However, the mRNA expression levels of *PRKCB* were higher in tumor tissues than in normal tissues in the OncoPrint database. It is possible that the expression levels of *PRKCB* may be affected by other genes, such as an imbalanced activation of




FIGURE 3 The expression quantitative trait loci (eQTLs) analysis from the 1000 Genomes Project. Correlation between *PRKCB* mRNA expression and rs34367566 genotypes in blood cells in the (A) additive model, (B) dominant model, (C) recessive model. mRNA, messenger RNA

the PPAP signaling pathway caused by mutations in the genes in tumor tissues, which may lead to abnormal expression of *PRKCB*. Future functional studies are necessary to elucidate the exact mechanism how *PRKCB* rs34367566 affects pancreatic cancer risk. Finally, the PPARs have been reported in numerous pathophysiological conditions, and many ligands have been designed to target PPARs receptors. However, to classify the therapeutic targets for drug development, more detailed mechanistic studies are needed.⁴⁵

The present study has several limitations. First of all, both of the two available pancreatic cancer GWAS data sets were from populations of European ancestry; therefore, the findings may not be generalized to other ethnic populations. Second, the access to clinical information, such as smoking, history of pancreatitis, diabetes, obesity, and other data relevant to risk, was limited and therefore could not be integrated into the model for further adjustment in the risk analysis. Finally, the biological mechanisms by which the SNPs of the identified genes may influence pancreatic cancer risk remain unclear. Therefore, additional comprehensive mechanistic studies are needed to validate our findings.

ACKNOWLEDGMENTS

The authors thank all the participants of the PanScan GWAS Study and Pancreatic Cancer Case Control Association Study. The authors would also like to acknowledge dbGaP repository for providing the cancer genotyping data set. Qingyi Wei was partly supported by the Duke Cancer Institute as part of the P30 Cancer Center Support Grant (Grant ID: NIH/NCI CA014236).

The PanScan project was funded in whole or in part with federal funds from the National Cancer Institute (NCI), US National Institutes of Health (NIH) under contract number HHSN261200800001E. Additional support was received from NIH/NCI K07 CA140790, the American Society of Clinical Oncology Conquer Cancer Foundation, the Howard Hughes Medical Institute, the Lustgarten Foundation, the Robert T. and Judith B. Hale Fund for Pancreatic Cancer Research, and Promises for Purple. A full list of acknowledgments for each participating study is provided in the Supplementary Note of the manuscript with PubMed ID: 25086665. The dbGaP accession number for this study used in this manuscript is phs000206.v5.p3.

The patients and controls for this study were derived from the following PANC4 studies: Johns Hopkins National Familial Pancreas Tumor Registry, Mayo Clinic Biospecimen Resource for Pancreas Research, Ontario Pancreas Cancer Study (OPCS), Yale University, MD Anderson Case Control Study, Queensland Pancreatic Cancer Study, University of California San Francisco Molecular Epidemiology of Pancreatic Cancer Study, International Agency of Cancer Research, and Memorial Sloan Kettering Cancer Center. This study is supported by NCI R01CA154823 Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN2682011000111. The dbGaP accession number for this study used in this manuscript is phs000648.v1.p1. The eQTL results published here were in whole or part based upon data generated by the TCGA Research Network: <https://www.cancer.gov/tcga>. The TCGA SNP data analyzed here were requested through dbGAP (accession#: phs000178.v11.p8).

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID

Qingyi Wei  <http://orcid.org/0000-0002-3845-9445>

REFERENCES

- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65(2):87-108.
- Tarver T. Cancer facts & figures 2012. American Cancer Society (ACS). *J Consum Health Internet*. 2012;16(3):366-367.
- Noone AM, Howlander N, Krapcho M, et al. *SEER Cancer Statistics Review, 1975-2015*. Bethesda, MD: National Cancer Institute. https://seer.cancer.gov/csr/1975_2015/

4. Schulte A, Pandeya N, Tran B, et al. Cigarette smoking and pancreatic cancer risk: more to the story than just pack-years. *Eur J Cancer*. 2014; 50(5):997-1003.
5. Koyanagi YN, Matsuo K, Ito H, et al. Body-mass index and pancreatic cancer incidence: a pooled analysis of nine population-based cohort studies with more than 340,000 Japanese subjects. *J Epidemiol*. 2018; 28(5):245-252.
6. Austin MA, Kuo E, Van Den Eeden SK, et al. Family history of diabetes and pancreatic cancer as risk factors for pancreatic cancer: the PACIFIC study. *Cancer Epidemiol Biomarkers Prev*. 2013;22(10):1913-1917.
7. Kirkegaard J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. *Am J Gastroenterol*. 2017;112(9):1366-1372.
8. Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. *JAMA*. 2018;319(23):2401-2409.
9. Nevler A, Muller AJ, Cozzitorto JA, et al. A sub-type of familial pancreatic cancer: evidence and implications of loss-of-function polymorphisms in indoleamine-2,3-dioxygenase-2. *J Am Coll Surg*. 2018;226(4):596-603.
10. Smith JP, Harms J, Matters GL, et al. A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer. *Cancer Biol Ther*. 2012;13(3):164-174.
11. Babic A, Bao Y, Qian ZR, et al. Pancreatic cancer risk associated with prediagnostic plasma levels of leptin and leptin receptor genetic polymorphisms. *Cancer Res*. 2016;76(24):7160-7167.
12. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. *Nat Genet*. 2009; 41(9):986-990.
13. Petersen GM, Amundadottir L, Fuchs CS, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. *Nat Genet*. 2010;42(3): 224-228.
14. Wolpin BM, Rizzato C, Kraft P, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nat Genet*. 2014;46(9):994-1000.
15. Childs EJ, Mucci E, Campa D, et al. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. *Nat Genet*. 2015;47(8):911-916.
16. Campa D, Rizzato C, Capurso G, et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. *Dig Liver Dis*. 2013;45(2): 95-99.
17. Wu C, Miao X, Huang L, et al. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. *Nat Genet*. 2011;44(1):62-66.
18. Low SK, Kuchiba A, Zembutsu H, et al. Genome-wide association study of pancreatic cancer in Japanese population. *PLoS One*. 2010; 5(7):e11824.
19. International Schizophrenia C, Purcell SM, Wray NR, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460(7256):748-752.
20. Wang S, Huo D, Ogundiran TO, et al. Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. *Mol Carcinog*. 2018;57(10):1311-1318.
21. Yu F, Tian T, Deng B, et al. Multi-marker analysis of genomic annotation on gastric cancer GWAS data from Chinese populations. *Gastric Cancer*. 2019;22(1):60-68.
22. Liao X, Yu L, Liu X, et al. Genome-wide association pathway analysis to identify candidate single nucleotide polymorphisms and molecular pathways associated with TP53 expression status in HBV-related hepatocellular carcinoma. *Cancer Manag Res*. 2018;10:953-967.
23. Duan B, Hu J, Liu H, et al. Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. *Int J Cancer*. 2018;142(7):1322-1331.
24. Wei P, Tang H, Li D. Insights into pancreatic cancer etiology from pathway analysis of genome-wide association study data. *PLoS One*. 2012;7(10):e46887.
25. Li D, Duell EJ, Yu K, et al. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. *Carcinogenesis*. 2012;33(7): 1384-1390.
26. Zhao J, Zhi Z, Song G, et al. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism could be a risk factor for gastric cancer. *Asian Pac J Cancer Prev*. 2015;16(6):2333-2340.
27. Lianggeng X, Baiwu L, Maoshu B, Jiming L, Youshan L. Impact of interaction between PPAR alpha and PPAR gamma on breast cancer risk in the Chinese Han population. *Clin Breast Cancer*. 2017;17(5):336-340.
28. Fesinmeyer MD, Stanford JL, Brentnall TA, et al. Association between the peroxisome proliferator-activated receptor gamma Pro12Ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: a pilot study. *Pancreas*. 2009;38(6):631-637.
29. Sansom OJ, Zabkiewicz J, Bishop SM, Guy J, Bird A, Clarke AR. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. *Oncogene*. 2003; 22(46):7130-7136.
30. Kondo E, Gu Z, Horii A, Fukushige S. The thymine DNA glycosylase MBD4 represses transcription and is associated with methylated p16(INK4a) and hMLH1 genes. *Mol Cell Biol*. 2005; 25(11):4388-4396.
31. Abdel-Rahman WM, Knuutila S, Peltomaki P, Harrison DJ, Bader SA. Truncation of MBD4 predisposes to reciprocal chromosomal translocations and alters the response to therapeutic agents in colon cancer cells. *DNA Repair (Amst)*. 2008;7(2):321-328.
32. Cortellino S, Turner D, Masciullo V, et al. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. *Proc Natl Acad Sci USA*. 2003;100(25):15071-15076.
33. Riccio A, Aaltonen LA, Godwin AK, et al. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability. *Nat Genet*. 1999;23(3):266-268.
34. Menoyo A, Alazzouzi H, Espin E, Armengol M, Yamamoto H, Schwartz S Jr. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. *Cancer Res*. 2001;61(21):7727-7730.
35. Bader S, Walker M, Hendrich B, et al. Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency. *Oncogene*. 1999;18(56):8044-8047.
36. Wong E, Yang K, Kuraguchi M, et al. Mbd4 inactivation increases Cright-arrowT transition mutations and promotes gastrointestinal tumor formation. *Proc Natl Acad Sci USA*. 2002;99(23):14937-14942.
37. Millar CB. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. *Science*. 2002;297(5580):403-405.
38. Kortmansky J, Schwartz GK. Bryostatins-1: a novel PKC inhibitor in clinical development. *Cancer Invest*. 2003;21(6):924-936.
39. Globe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. *Cancer Metastasis Rev*. 1994;13(3-4):411-431.
40. Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. *FASEB J*. 1999;13(13): 1658-1676.
41. Kiley SC, Clark KJ, Goodnough M, Welch DR, Jaken S. Protein kinase C delta involvement in mammary tumor cell metastasis. *Cancer Res*. 1999;59(13):3230-3238.
42. Aziz MH, Hafeez BB, Sand JM, et al. Protein kinase C δ mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with

- MAPK cascade (RAF-1, MEK1/2, and ERK1/2). *Oncogene*. 2010;29(21):3100-3109.
43. Satoh A, Gukovskaya AS, Nieto JM, et al. PKC-delta and -epsilon regulate NF-kappaB activation induced by cholecystokinin and TNF-alpha in pancreatic acinar cells. *Am J Physiol Gastrointest Liver Physiol*. 2004;287(3):G582-G591.
44. Satoh A, Gukovskaya AS, Reeve JR Jr., Shimosegawa T, Pandol SJ. Ethanol sensitizes NF-kappaB activation in pancreatic acinar cells through effects on protein kinase C-epsilon. *Am J Physiol Gastrointest Liver Physiol*. 2006;291(3):G432-G438.
45. Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications. *Eur J Med Chem*. 2019;166:502-513.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Liu X, Qian D, Liu H, et al. Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer. *Molecular Carcinogenesis*. 2020;1-10.
<https://doi.org/10.1002/mc.23208>